Chemomab Therapeutics Q1 EPS $(0.04) Misses $(0.03) Estimate

Benzinga · 05/11/2023 06:01
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 81.82 percent decrease over losses of $(0.02) per share from the same period last year.